Michael Slade

Assistant Professor

Washington University in St. Louis

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Michael Slade is an Assistant Professor at Washington University in St. Louis, USA. His research focuses on hematology and transplant medicine, with recent publications addressing topics such as Multiple Myeloma, T-cell receptor engineering, and donor-specific antibody management in haploidentical hematopoietic cell transplants. He actively contributes to advancements in patient care through his studies on the prognostic value of blood-based measurable residual disease and the management of venous thromboembolism risk in cancer treatments.

Articles (19)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2020

Collaborators (16)

Feng Gao

Associate Professor

Washington University in St. Louis

UNITED STATES

Michael Slade

Research Interests

Explore related searches

Contact this professor

About

Articles (19)

Blood-Based Measurable Residual Disease by Clonotypic Mass Spectrometry is Prognostic in Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplant

Episteme

Rational Protein Engineering to Enhance MHC-Independent T-cell Receptors

False-positive human immunodeficiency virus nuclear acid amplification technique testing following therapy with transgenic T cell receptor cellular therapy for synovial sarcoma

Pretransplant desensitization of donor-specific anti-HLA antibodies with plasmapheresis and immunoglobulin produces equivalent outcomes to patients with no donor specific antibodies in haploidentical hematopoietic cell transplant

Venous Thromboembolism Risk in Patients With Newly Diagnosed Multiple Myeloma Treated with Carfilzomib or Bortezomib in Combination With Lenalidomide and Dexamethasone

A Single Reference Interval for Interpreting Serum Free Light Chains across Patients with Varying Renal Function

Evaluation of the Simplified Score to Predict Early Relapse in Multiple Myeloma (S-ERMM) in the MMRF CoMMpass study

Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: Outcomes from 15 U.S. institutions.

What You Deserve

Costimulatory domains direct distinct fates of CAR-driven T cell dysfunction

Persistent Molecular Disease in Adult Patients With AML Evaluated With Whole-Exome and Targeted Error-Corrected DNA Sequencing.

Continuous Elotuzumab, Pomalidomide, and Dexamethasone Maintenance Following Second Autologous Transplantation for Multiple Myeloma: Results of a Prospective Phase 2 Multicenter Trial

Cycles

Impact of donor age and relationship on outcomes of peripheral blood haploidentical hematopoietic cell transplantation

Ixazomib, lenalidomide and dexamethasone consolidation with randomized ixazomib or lenalidomide maintenance after autologous transplant in newly diagnosed multiple myeloma

The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis

A Small Cemetery

CD123 bi-specific antibodies in development in AML: What do we know so far?

Collaborators (16)

Feng Gao

Peter Riedell

Keith Stockerl-Goldstein

Ramzi Abboud

Kristen Sanfilippo

James Godfrey

Mark Fiala

John L. Frater

Craig Hofmeister

Armin Ghobadi

David H. Spencer

Chang Liu

Neil Anderson

Marina Terekhova

Timothy Voorhees

Ajay Major

Make your next move.